BioDelivery Sciences

BioDelivery Sciences is a pharmaceutical company that focuses on pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ARCA biopharma

Dare Bioscience

G Medical Innovations Holdings Ltd

Jaguar Health

Luokung Technology Corp

Exela Technologies

Are these Reddit penny stocks the best 7 to watch in July 2021? The post Best Reddit Penny Stocks to Buy Now?

Best Reddit Penny Stocks to Buy Now? 7 for Your July Small-Caps List

BDSI has been doing very well with product sales. However, it has never seen the peak it saw during approvals of lead drugs.

BioDelivery Sciences: Clinic-To-Market Transition Problem

BioDelivery Sciences International, Inc. (BDSI) CEO Jeffrey Bailey on Q1 2021 Results - Earnings Call Transcript

BioDelivery (BDSI) delivered earnings and revenue surprises of -28.57% and 0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BioDelivery Sciences International (BDSI) Misses Q1 Earnings Estimates

Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year Net Income of $5.2 Million, EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today

BioDelivery Sciences Reports First Quarter 2021 Results

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?

Co-Diagnostics

Kamada

Surface Oncology Inc

Viemed Healthcare

As of April 21, the GuruFocus All-in-One Screener, a Premium feature, found that the following guru-owned utilities have low price-earnings ratios. While some of them are great value investments, others may need to be researched more carefully, according to the discounted cash flow calculator.

5 Health Care Stocks Trading with Low Price-Earnings Ratios

RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 6, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021

Blueprint Medicines

Fulgent Genetics

If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.

3 Magic Formula Health Care Stock Picks

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock?

BioDelivery (BDSI) Down 12.8% Since Last Earnings Report: Can It Rebound?

BioDelivery Sciences (BDSI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: BioDelivery Sciences (BDSI)

Southwestern Energy

Truecar Inc

Waitr Holdings Inc

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Well-Known Companies Highlight Stocks to Buy Under $10 With Huge Potential

BioDelivery Sciences International, Inc. (BDSI) CEO Jeff Bailey on Q4 2020 Results - Earnings Call Transcript

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues.

BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up

Shares of BioDelivery Sciences Intl (NASDAQ:BDSI) rose 6.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 66.67% year over year to $0.10, which beat the estimate of $0.06.

Recap: BioDelivery Sciences Q4 Earnings

On Wednesday, March 10, BioDelivery Sciences Intl (NASDAQ:BDSI) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings Preview: BioDelivery Sciences Intl

LiveXLive Media

Limelight Networks

Nokia

OrganiGram Holdings Inc.

OPKO Health

These seven penny stocks are most likely to push through the $5 mark having built a significant head of steam in the past year. The post 7 Penny Stocks Close To Busting Through the $5 Mark appeared first on InvestorPlace.

7 Penny Stocks Close To Busting Through the $5 Mark

RALEIGH, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full year 2020 financial results before the open of the U.S. financial markets on Wednesday, March 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory OutcomesComparing BELBUCA® to Oxycodone on January 16 from 1:10pm – 2:10pm CT

BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting

BioMarin Pharmaceutical

Catalyst Pharmaceuticals

Innoviva

Novavax

Vertex Pharmaceuticals

Vaxart

Voyager Therapeutics

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Biotech Stocks for Q1 2021

BioDelivery (BDSI) Up 9.5% Since Last Earnings Report: Can It Continue?

RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 32nd Annual Healthcare Conference.

BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference

Let's see if BioDelivery Sciences International (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.

Is a BioDelivery Sciences (BDSI) Good Value Investor Stock?

RALEIGH, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in the virtual Southwest IDEAS Investor Conference on November 18, 2020. BDSI's presentation will be webcasted and is scheduled to be available at 7:00 am CST on November 18. The presentation can be accessed through the Southwest IDEAS conference portal for registered participants, in the investor relations section of the Company's website: www.bdsi.com, and on the IDEAS conference website: www.IDEASconferences.com.

BioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18

BioDelivery Sciences International, Inc. (BDSI) CEO Jeff Bailey on Q3 2020 Results - Earnings Call Transcript

News for BioDelivery Sciences Stock (BDSI)